$GTBP News
Last published 2d ago
- 2d agoGTBPGT Biopharma Oral Presentation at the SITC 2026 Annual MeetingGlobeNewswireGT Biopharma showcased new preclinical data in an oral presentation at SITC demonstrating an enhanced effect of combining GTB-5550, a B7-H3-targeted tri-specific NK cell engager (TriKE®), with a KRAS inhibitor (KRASi),
- 2w agoGTBPMRNAIOVAGMAB+1Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment MarketGlobeNewswireNEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Cancer treatment is moving into a new phase, and immuno-oncology is right at the center of it. Instead of relying only on drugs that attack tumors directly, researchers are
- 2w agoGTBPGT Biopharma Selected for Oral Presentation at the SITC 2026 Annual MeetingGlobeNewswireSAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on
- 1mo agoGTBPGT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple MyelomaGlobeNewswireFDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant
- 2mo agoGTBPGT Biopharma Reports Second Quarter 2026 Financial ResultsGlobeNewswirePhase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 initiated May 2026
- 4mo agoGTBPNKTXFATECMPX+1A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting DrugsPR NewswireDrug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital ...
- 5mo agoCMPXCRBUFATEGTBP+1After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune CellGlobeNewswireIssued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for
- 5mo agoFATEGTBPIBRXIOVA+1Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetGlobeNewswireIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while
- 5mo agoGTBPIPHAINKTIPSCA Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyPR NewswireMost clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT...
- 5mo agoGTBPGT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological InitiativesGlobeNewswireIncreased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs
- 5mo agoGTBPIBRXFATENKTX+1The $13 Million Company Teaching the Immune System to Hunt CancerPR NewswireUSA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)...
- 5mo agoGTBPFATENKTXIBRX+1Three TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesPR NewswireThe case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first ...
- 5mo agoGTBPSMMTIDYAGSK+1B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters ClinicPR NewswireUSA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could ...
- 6mo agoGTBPGT Biopharma Reports First Quarter 2026 Financial ResultsGlobeNewswirePhase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3
- 6mo agoGTBPONCYSNSEVIR"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesGlobeNewswireIssued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly
- 6mo agoGTBPIDYARADXSMMTA Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in OncologyGlobeNewswireIssued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new natural killer cell
- 6mo agoGTBPARTVFATEIBRX+1Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhasePR NewswireMomentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across...
- 6mo agoGTBPGT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid TumorsGlobeNewswireGTB-5550 is now the 3rd TriKE® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation phase
- 8mo agoGTBPGT Biopharma Reports Full Year 2025 Financial ResultsGlobeNewswirePhase 1 trial evaluating GTB-3650 TriKE® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating GTB-5550
- 8mo agoGTBPGT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth ConferenceGlobeNewswireSAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the
- 9mo agoGTBPGT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3GlobeNewswireGTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of
- 9mo agoAMCOFGTBPLVGLFVPTDFTHE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material CycleGlobeNewswireVANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Equity Insider Market Intelligence Brief – The 2026 economy has hit the wall of physical limits. After a decade of rewarding "potential," the
- 9mo agoGTBPIBRXERASCHRS+1Functional Force: Precision Platforms Disrupt the 2026 Tumor LandscapePR NewswireEquity Insider News Commentary – The precision medicine sector is undergoing a structural realignment toward platform-based biologics, as the market...
- 10mo agoGTBPGT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancersGlobeNewswireGT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cash runway into Q3
- 10mo agoCRBUGTBPLYELNRIX+1Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market SurgeGlobeNewswireVANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a
- 10mo agoGTBPADCTSTROCRNX+1Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma PipelinesPR NewswireEquity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning...
- 10mo agoGTBPREGNGMABAUTL+1Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030PR NewswireUSA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combination for second-line blood cancer...
- 11mo agoAVAIGHVNFGTBPONCY+1THE VISIBILITY INDEX: 5 Companies Solving the Invisible CrisisGlobeNewswireVANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – The market is repricing risk around a single variable: detection. The most dangerous threats are the ones
- 11mo agoGTBPERASFHTXOABI+1Platform Technologies Drive $211B Surge in Precision Cancer TreatmentPR NewswireEquity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies...
- 11mo agoDGNXGTBPLVGLFTHE REALITY CHECK: 5 Assets Delivering Proof in a Speculative MarketGlobeNewswireIssued on behalf of Quantum Security Encryption Corp. VANCOUVER, British Columbia, Dec. 11, 2025 (GLOBE NEWSWIRE) -- EquityInsider.com Market Intelligence Brief The capital rotation is underway. After years of
- 11mo agoGTBPGERNKURASLS+1Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection PointsPR NewswireTriple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die...
- 11mo agoGTBPGT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 TrialsACCESS NewswireNAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face limited treatment options and uncertain outcomes. Scientists have increasingly turned to the body's own defenses,
- 12mo agoGTBPGT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE® IND
- 1y agoGTBPGT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic MalignanciesGlobeNewswireThe formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing advancement into Cohort 4 with a dose of 10 ug/kg/day Actively screening
- 1y agoGTBPEVAXRNXTEDAP+1Natural Killer Cell Therapies Lead $254B Immunotherapy Market TransformationPR NewswireEquity InsiderNews Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more...
- 1y agoGTBPNRIXGRALCCCC+1Precision Oncology Approaches Drive $312B Market TransformationPR NewswireUSA News Group News Commentary – Biomarker-driven drug development accelerates across oncology as companies advance novel mechanisms targeting...
- 1y agoGTBPLXEOANIXTEM+1Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034PR NewswireOhio State researchers recently solved a critical mystery explaining why some cancer immunotherapies fail[1], while a University of Chicago team...
- 1y agoGTBPGT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic MalignanciesGlobeNewswireThe Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date The first
- 1y agoGTBPLPTXIOBTCELC+1Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 BillionPR NewswireUSA News Group News Commentary – Major pharmaceutical companies are unveiling breakthrough cancer data at the European Society for Medical Oncology...
- 1y agoGTBPIMABENGNONCO+1Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment ParadigmsPR NewswireEquity InsiderNews Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are...
- 1y agoGTBPGT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas SummitGlobeNewswireSAN FRANCISCO, CALIFORNIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the
- 1y agoGTBPGT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireThe Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory (r/r) CD33
- 1y agoGTBPGT Biopharma Reports Second Quarter 2025 Financial ResultsGlobeNewswireGTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and initiated dosing
- 1y agoGTBPGT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2GlobeNewswireThe first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observedThe company plans on
- 1y agoGTBPGT Biopharma Appoints New Member to its Board of DirectorsGlobeNewswireSAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the
- 1y agoGTBPGT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation SignalsGlobeNewswireFollowing the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results from Phase 1 later
- 1y agoGTBPGT Biopharma Appoints New Member to its Board of DirectorsGlobeNewswireSAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the
- 1y agoGTBPGT Biopharma to Participate in the 10th Anniversary of the Innate Killer SummitGlobeNewswireSAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the
- 1y agoGTBPGT Biopharma Announces Exercise of WarrantsGlobeNewswireSAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the
- 1y agoGTBPGT Biopharma Announces Request for Withdrawal of Form S-1 Registration StatementGlobeNewswireSAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the